DABRAFENIB 75MG

DABRAFENIB 75MG Trade Information

Minimum Order Quantity
1 Piece

FOB Port
INDIA

Payment Terms
Cash Advance (CA), Cash in Advance (CID), Letter of Credit at Sight (Sight L/C), Telegraphic Transfer (T/T), Western Union, Letter of Credit (L/C), Cheque, Days after Acceptance (DA), Delivery Point (DP)

Supply Ability
100 Pieces Per Month

Delivery Time
3 Days

Sample Available
Yes

Sample Policy
Free samples available with shipping and taxes paid by the buyer

Packaging Details
BOTTLE

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

Certifications
GMP COA INVOICE

About DABRAFENIB 75MG

DABRAFNIB is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.

Dabra is indicated, in combination with trametinib, for:

the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.

the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.

the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Limitations of Use: Dabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.

DOSAGE AND USE:

The recommended dosage of Dabra is 150 mg orally twice daily. Take Dabra at least 1 hour before or at least 2 hours after a meal.

Capsule should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20C to 25C.

Tell us about your requirement